```html

Zollinger‑Ellison Plasma Cell Dyscrasia: A Comprehensive Patient Guide

Overview

Zollinger‑Ellison plasma cell dyscrasia (ZE‑PCD) is an exceptionally rare disorder that combines two distinct entities:

• Zollinger‑Ellison syndrome (ZES): a gastrin‑producing neuroendocrine tumor (gastrinoma) that causes severe acid hypersecretion.
• Plasma cell dyscrasia (PCD): a clonal proliferation of plasma cells that can range from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma.

When a patient simultaneously presents with a gastrinoma and an underlying clonal plasma‑cell disorder, clinicians use the term “Zollinger‑Ellison plasma cell dyscrasia.” Because both conditions are uncommon on their own, the combined syndrome is seen in fewer than 1 per million people worldwide.

Who it affects: The average age at diagnosis is 55 – 65 years, with a slight male predominance (≈ 55 % male). Most cases are sporadic; a minority arise in the context of inherited syndromes such as Multiple Endocrine Neoplasia type 1 (MEN‑1).

Prevalence & incidence (estimates from the National Cancer Institute and the International Myeloma Working Group):

• Zollinger‑Ellison syndrome: ~1–3 cases per million per year.
• Plasma cell dyscrasias: ~5–7 cases per 100,000 adults.
• Combined ZE‑PCD: < 0.1 case per million (only case series and isolated reports exist).

Symptoms

The clinical picture reflects the additive effects of acid hypersecretion and plasma‑cell‑related organ involvement. Symptoms may be intermittent early on and become more pronounced as disease progresses.

Gastrinoma‑related (Zollinger‑Ellison) symptoms

• Recurrent abdominal pain: Burning or gnawing pain that worsens 2–3 hours after meals.
<
• Peptic ulcer disease: Multiple duodenal ulcers (often > 3 cm), sometimes perforated or bleeding.
• Diarrhea & steatorrhea: Acid inactivates pancreatic enzymes, leading to fat malabsorption.
• Esophagitis & gastroesophageal reflux: Chronic heartburn unresponsive to OTC antacids.
• Weight loss: Result of malabsorption and chronic pain.
• Nausea / vomiting: May occur with gastric outlet obstruction from ulcer scarring.

Plasma‑cell‑related symptoms

• Bone pain: Common in the spine, ribs, or pelvis due to lytic lesions.
• Pathologic fractures: Even low‑impact trauma can cause a break.
• fatigue & anemia: From bone‑marrow infiltration.
• Hypercalcemia: Can cause constipation, polyuria, confusion, and kidney stones.
• Renal insufficiency: Light‑chain (Bence‑Jones) protein deposition.
• Peripheral neuropathy: Rare, caused by amyloid deposition.
• Increased susceptibility to infections: Due to impaired normal immunoglobulin production.

Combined presentation

Patients often notice gastrointestinal symptoms first, which delay the recognition of an underlying plasma‑cell disorder. Overlap may lead to:

• Severe, refractory peptic ulcer disease that does not heal despite proton‑pump inhibitor (PPI) therapy.
• Unexplained anemia with both iron deficiency (from GI bleeding) and anemia of chronic disease (from marrow involvement).
• Worsening renal function secondary to both hypercalcemia and acid‑related nephropathy.

Causes and Risk Factors

Because ZE‑PCD is a convergence of two distinct pathologies, its etiology is multifactorial.

Gastrinoma (Zollinger‑Ellison) causes

• Genetic mutations: MEN1 gene loss‑of‑function; CDKN1B rarely.
• Somatic mutations: ATRX, DAXX, and RAF1 have been described in sporadic gastrinomas.

Plasma cell dyscrasia causes

• Clonal plasma‑cell proliferation: Driven by complex genetic events (e.g., translocations involving the IgH locus on chromosome 14).
• Environmental exposures: Radiation, benzene, and certain pesticides increase risk.
• Chronic immune stimulation: Autoimmune diseases or persistent infections (e.g., HIV) may predispose.

Risk factors for the combined syndrome

• Family history of MEN‑1 or other endocrine tumors.
• Prior diagnosis of MGUS or smoldering myeloma.
• Age > 50 years (cumulative risk of somatic mutations).
• Male sex (slightly higher incidence of gastrinomas).
• Exposure to ionizing radiation (e.g., therapeutic radiation for other cancers).

Diagnosis

Diagnosis requires confirming both components with a coordinated, multidisciplinary approach (gastroenterology, endocrinology, hematology/oncology, radiology, pathology).

Step‑by‑step diagnostic pathway

1. Clinical suspicion: Persistent refractory peptic ulcer disease + unexplained anemia, hypercalcemia, or bone pain.
2. Laboratory studies:
   • Serum gastrin level (fasting, > 1000 pg/mL highly suggestive of gastrinoma).
   • Secretin stimulation test (gastrin rises > 120 pg/mL after IV secretin).
   • Serum calcium, creatinine, and albumin.
   • Complete blood count (CBC) and peripheral smear.
   • Serum protein electrophoresis (SPEP) with immunofixation; urine protein electrophoresis (UPEP) for Bence‑Jones protein.
   • Serum free light‑chain assay (kappa/lambda ratio).
3. Imaging for gastrinoma:
   • Contrast‑enhanced CT abdomen/pelvis (sensitivity ≈ 73 %).
   • Multiphasic MRI (higher soft‑tissue resolution).
   • Somatostatin‑receptor scintigraphy (OctreoScan) or ^68Ga‑DOTATATE PET/CT (sensitivity > 90 %).
   • EUS (endoscopic ultrasound) for small pancreatic lesions.
4. Imaging for plasma‑cell disease:
   • Skeletal survey (X‑ray) or low‑dose whole‑body CT for lytic lesions.
   • Whole‑body ^18F‑FDG PET/CT for active myeloma.
5. Biopsy & pathology:
   • Endoscopic biopsy of ulcer or tumor for gastrinoma histology (positive chromogranin A, synaptophysin, gastrin immunostain).
   • Bone marrow aspirate/biopsy to assess plasma‑cell percentage, cytogenetics, and light‑chain restriction.
6. Staging: Use the TNM system for gastrinoma (AJCC 8th edition) and the Revised International Staging System (R‑ISS) for plasma‑cell disease.

Key diagnostic criteria

Diagnosis of ZE‑PCD is made when a patient meets:

• Biochemical + imaging confirmation of a gastrinoma.
• Evidence of a clonal plasma‑cell proliferative disorder (MGUS, smoldering myeloma, or overt multiple myeloma) according to WHO 2022 criteria.

Treatment Options

Management must address both disease components, often simultaneously.

1. Treating the gastrinoma (Zollinger‑Ellison)

• Acid suppression (first‑line): High‑dose PPIs (e.g., omeprazole 60 mg daily or equivalent) or potassium‑competitive acid blockers (vonoprazan 20 mg daily). Aim for symptom control and ulcer healing.
• Surgical resection:
  • Enucleation or segmental pancreaticoduodenectomy for localized tumors.
  • Curative intent when disease is confined (≈ 70 % 5‑year survival).
• Somatostatin analogues: Octreotide LAR or lanreotide for unresectable or metastatic disease; also reduce gastrin secretion.
• Targeted systemic therapy: Everolimus or sunitinib (used for neuroendocrine tumors) when disease progresses.
• Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE in patients with high somatostatin‑receptor expression.

2. Treating the plasma‑cell dyscrasia

• MGUS / Smoldering myeloma: Active surveillance with labs every 3–6 months; no immediate therapy.
• Symptomatic multiple myeloma:
  • Induction: Bortezomib‑cyclophosphamide‑dexamethasone (VCD) or bortezomib‑lenalidomide‑dexamethasone (VRd). Choice guided by renal function and frailty.
  • Autologous stem‑cell transplant (ASCT) in eligible patients (< 70 y, good performance status).
  • Maintenance: Lenalidomide or ixazomib for 2–3 years.
• Supportive care: Bisphosphonates (zoledronic acid) or denosumab for bone disease; erythropoiesis‑stimulating agents for anemia; hydration & alkalinization for renal protection.

3. Integrated care considerations

• Coordinate PPI therapy with myeloma treatment (high‑dose PPIs can affect absorption of some oral antineoplastic agents; monitor drug levels).
• Monitor calcium and vitamin D closely; both conditions influence bone health.
• Multidisciplinary tumor board review is recommended to prioritize surgery vs. systemic therapy based on disease burden.

4. Lifestyle & supportive recommendations

• Low‑acid diet (avoid caffeine, alcohol, spicy foods) to complement PPIs.
• Calcium‑rich, vitamin‑D‑adequate diet, but limit calcium supplements if hypercalcemia is present.
• Stay hydrated (≥ 2 L/day) to protect kidneys.
• Smoking cessation and regular aerobic exercise (150 min/week) improve overall outcomes.

Living with Zollinger‑Ellison Plasma Cell Dyscrasia

Managing a rare dual diagnosis can feel overwhelming. Below are practical tips to improve daily quality of life.

Medication adherence

• Use a weekly pill organizer and set phone alarms for PPIs (usually taken before meals).
• Keep a medication list (name, dose, timing) and share it with every provider.
• Report side‑effects promptly; dose adjustments of bortezomib or PPIs are common.

Monitoring & follow‑up

• Lab schedule (example):
  Every 3 months: CBC, calcium, creatinine, serum free light chains, gastrin level.
  Every 6 months: SPEP/UPEP, liver panel, fasting lipid profile.
  Annually: Whole‑body imaging (PET/CT or low‑dose CT) and endoscopic evaluation if ulcer disease persists.
• Use an electronic health‑record portal to track results and receive reminders.

Nutrition

• Small, frequent meals (4–6 times daily) reduce acid load.
• High‑protein, low‑fat diet aids in maintaining lean body mass, especially when on chemotherapy.
• If malabsorption is severe, a registered dietitian may recommend medium‑chain triglyceride (MCT) oil supplements.

Psychosocial support

• Join rare‑disease support groups (e.g., RareConnect, National Organization for Rare Disorders).
• Consider counseling for anxiety or depression, which affect up to 30 % of patients with chronic GI or hematologic cancers.
• Family education reduces misunderstanding about the need for long‑term medication.

Physical activity

• Weight‑bearing exercises (walking, resistance bands) 2–3 times per week help preserve bone density.
• Avoid high‑impact sports if lytic bone lesions are present.

Prevention

Because ZE‑PCD involves both a sporadic tumor and a clonal plasma‑cell process, primary prevention is limited. However, risk reduction strategies for each component are helpful.

• Limit exposures: Reduce occupational contact with benzene, asbestos, and ionizing radiation.
• Healthy lifestyle: Maintain a BMI < 25 kg/m², avoid smoking, limit alcohol (< 2 drinks/day).
• Screen high‑risk families: Individuals with known MEN‑1 mutations should undergo periodic fasting gastrin checks and imaging per endocrine guidelines.
• Early MGUS detection: Routine serum protein electrophoresis in adults > 50 years with unexplained anemia or kidney dysfunction helps catch plasma‑cell dyscrasia before progression.

Complications

If left untreated or inadequately controlled, ZE‑PCD can lead to serious, potentially life‑threatening complications.

From the gastrinoma

• Bleeding duodenal ulcers → anemia, transfusion dependence.
• Perforation → acute abdomen, surgical emergency.
• Stricture formation → gastric outlet obstruction.
• Metastatic disease (liver, lymph nodes) → refractory hyperacidic state.
• Acid‑related kidney injury (acidic nephropathy).

From the plasma‑cell disorder

• Pathologic fractures & spinal cord compression.
• Renal failure due to light‑chain cast nephropathy.
• Hyperviscosity syndrome (rare, but possible with high IgM levels).
• Secondary infections (immunoparesis).
• Peripheral neuropathy and amyloidosis.

Combined impact

• Severe malnutrition from chronic diarrhea + high metabolic demand of myeloma.
• Increased cardiovascular risk due to chronic inflammation and hypercalcemia.
• Reduced tolerance to chemotherapy because of ongoing GI ulcer disease.

When to Seek Emergency Care

---

**References** (accessed May 2026)

• American College of Gastroenterology. Guidelines for the Diagnosis and Management of Zollinger‑Ellison Syndrome. Gastroenterology. 2023.
• National Cancer Institute. Neuroendocrine Tumors (Gastrinomas) Treatment (PDQ®) – Health Professional Version. Updated 2024.
• International Myeloma Working Group. 2022 IMWG Criteria for the Diagnosis of Multiple Myeloma. Blood. 2022.
• Mayo Clinic. Zollinger‑Ellison syndrome. Patient education page. 2024.
• Cleveland Clinic. Plasma Cell Dyscrasias Overview. 2023.
• World Health Organization. Classification of Tumours of the Digestive System, 5th ed. 2023.
• National Comprehensive Cancer Network (NCCN). Guidelines for Neuroendocrine and Multiple Myeloma, Version 3.2024.

```